Evercore, alongside Citi, has been enlisted as the financial advisor for Eli Lilly in its strategic acquisition of Morphic Holding, Inc., a deal poised to reshape treatment options for inflammatory bowel disease (IBD).
Valued at approximately $3.2 billion, this acquisition will see Lilly purchasing all outstanding shares of Morphic for $57 each, a significant premium over recent trading prices.
This move is approved by